** California-based drug developer Denali Therapeutics DNLI.O rise 11.4% to $13.70
** DNLI says it has started the rolling submission of a marketing application for accelerated FDA approval of its experimental drug, tividenofusp alfa, to treat a type of rare genetic disorder called Hunter syndrome
** Co says the drug is currently enrolling patients for a late-stage study
** Hunter syndrome is where the body lacks an enzyme needed to break down certain sugars, causing these sugars to build up in the body, leading to various health problems
** Co expects to complete the submission of marketing application in the first half of May 2025
** DNLI plans a potential U.S. commercial launch in late 2025 or early 2026
** Stock has fallen 34.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。